Polycystic kidney disease interventions: Difference between revisions
| Line 27: | Line 27: | ||
*Renal failure | *Renal failure | ||
== | ==Dialysis== | ||
*Dialysis is the mainstay of treatment for ESRD and renal failure in patients with polycystic kidney disease<ref name="pmid9044324">{{cite journal |vauthors=Pirson Y, Christophe JL, Goffin E |title=Outcome of renal replacement therapy in autosomal dominant polycystic kidney disease |journal=Nephrol. Dial. Transplant. |volume=11 Suppl 6 |issue= |pages=24–8 |date=1996 |pmid=9044324 |doi= |url=}}</ref> | |||
*Peritoneal dialysis is not preferred in patients with PKD, because of the lack of ability to acoomodate large volume of peritoneal fluid<ref name="pmid10695753">{{cite journal |vauthors=Lederman ED, McCoy G, Conti DJ, Lee EC |title=Diverticulitis and polycystic kidney disease |journal=Am Surg |volume=66 |issue=2 |pages=200–3 |date=February 2000 |pmid=10695753 |doi= |url=}}</ref> | |||
*Peritoneal dialysis is also avoided in patients with aortic aneurysms | |||
*Peritoneal dialysis may have a survival benefit over hemodialysis<ref name="pmid11924752">{{cite journal |vauthors=Abbott KC, Agodoa LY |title=Polycystic kidney disease at end-stage renal disease in the United States: patient characteristics and survival |journal=Clin. Nephrol. |volume=57 |issue=3 |pages=208–14 |date=March 2002 |pmid=11924752 |doi= |url=}}</ref> | |||
*Hemodialysis is the preferred modality for renal replacement in patients with polycystic kidney disease<ref name="pmid9044324">{{cite journal |vauthors=Pirson Y, Christophe JL, Goffin E |title=Outcome of renal replacement therapy in autosomal dominant polycystic kidney disease |journal=Nephrol. Dial. Transplant. |volume=11 Suppl 6 |issue= |pages=24–8 |date=1996 |pmid=9044324 |doi= |url=}}</ref> | |||
**Anticoagulants required for hemodialysis should be used with caution due to pre existing hematuria | |||
==Contraindications== | ==Contraindications== | ||
Revision as of 15:05, 8 June 2018
|
Polycystic kidney disease Microchapters |
|
Differentiating Polycystic kidney disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Polycystic kidney disease interventions On the Web |
|
American Roentgen Ray Society Images of Polycystic kidney disease interventions |
|
Risk calculators and risk factors for Polycystic kidney disease interventions |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: M. Khurram Afzal, MD [2]
Overview
There are no recommended therapeutic interventions for the management of [disease name].
OR
[Name of intervention] is not the first-line treatment option for patients with [disease name]. [Name of intervention] is usually reserved for patients with either [indication 1], [indication 2], and [indication 3]
OR
The mainstay of treatment for [disease name] is medical therapy/surgery. [Name of intervention] is usually reserved for patients with either [indication 1], [indication 2], and/or [indication 3].
OR
The feasibility of [name of intervention] depends on the stage of [disease or malignancy] at the time of diagnosis.
OR
[Name of intervention] is the mainstay of treatment for [disease or malignancy].
Indications
Dialysis is not the first-line treatment option for patients with polycystic kidney disease. Dialysis is usually reserved for patients with either:[1]
- End stage renal disease (ESRD)
- Renal failure
Dialysis
- Dialysis is the mainstay of treatment for ESRD and renal failure in patients with polycystic kidney disease[2]
- Peritoneal dialysis is not preferred in patients with PKD, because of the lack of ability to acoomodate large volume of peritoneal fluid[3]
- Peritoneal dialysis is also avoided in patients with aortic aneurysms
- Peritoneal dialysis may have a survival benefit over hemodialysis[4]
- Hemodialysis is the preferred modality for renal replacement in patients with polycystic kidney disease[2]
- Anticoagulants required for hemodialysis should be used with caution due to pre existing hematuria
Contraindications
References
- ↑ Grantham JJ (October 2008). "Clinical practice. Autosomal dominant polycystic kidney disease". N. Engl. J. Med. 359 (14): 1477–85. doi:10.1056/NEJMcp0804458. PMID 18832246.
- ↑ 2.0 2.1 Pirson Y, Christophe JL, Goffin E (1996). "Outcome of renal replacement therapy in autosomal dominant polycystic kidney disease". Nephrol. Dial. Transplant. 11 Suppl 6: 24–8. PMID 9044324.
- ↑ Lederman ED, McCoy G, Conti DJ, Lee EC (February 2000). "Diverticulitis and polycystic kidney disease". Am Surg. 66 (2): 200–3. PMID 10695753.
- ↑ Abbott KC, Agodoa LY (March 2002). "Polycystic kidney disease at end-stage renal disease in the United States: patient characteristics and survival". Clin. Nephrol. 57 (3): 208–14. PMID 11924752.